Synergistic Anti-Tumor Activity, Reduced Perk, and Immuno-Stimulatory Cytokine Profiles with 5-FU or ONC212 Plus KRAS G12D Inhibitor MRTX1133 in CRC and Pancreatic Cancer Cells Independent of G12D Mutation
AMERICAN JOURNAL OF CANCER RESEARCH（2024）
Key words
MRTX1133,KRAS G12D,pancreatic cancer,colorectal cancer,cytokine,drug synergy,ONC212
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined